Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature.
HIV
Multiple sclerosis
Natalizumab
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
04
02
2023
accepted:
01
03
2023
medline:
12
6
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
To date, few cases of multiple sclerosis (MS) patients with concomitant Human Immunodeficiency Virus (HIV) infection have been described. However, none of the previously described cases has been treated with Natalizumab, probably due to the increasing risk of progressive multifocal leukoencephalopathy (PML). We report the case of a patient concomitantly diagnosed for HIV infection and MS treated with combined antiretroviral therapy (cART) and Natalizumab for 19 months, without clinical or radiological MS activity. Our case might suggest considering Natalizumab in patients with concomitant HIV infection, especially for those with significant disease activity requiring a high efficacy disease modifying treatment.
Sections du résumé
BACKGROUND
BACKGROUND
To date, few cases of multiple sclerosis (MS) patients with concomitant Human Immunodeficiency Virus (HIV) infection have been described. However, none of the previously described cases has been treated with Natalizumab, probably due to the increasing risk of progressive multifocal leukoencephalopathy (PML).
CASE
METHODS
We report the case of a patient concomitantly diagnosed for HIV infection and MS treated with combined antiretroviral therapy (cART) and Natalizumab for 19 months, without clinical or radiological MS activity.
CONCLUSIONS
CONCLUSIONS
Our case might suggest considering Natalizumab in patients with concomitant HIV infection, especially for those with significant disease activity requiring a high efficacy disease modifying treatment.
Identifiants
pubmed: 36930389
doi: 10.1007/s10072-023-06727-7
pii: 10.1007/s10072-023-06727-7
doi:
Substances chimiques
Natalizumab
0
Antibodies, Monoclonal, Humanized
0
Immunologic Factors
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2305-2309Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. Fondazione Società Italiana di Neurologia.
Références
Coban A et al (2007) Multiple sclerosis–like clinical and magnetic resonance imaging findings in human immunodeficiency virus positive-case. Neurologist 13:154–157. https://doi.org/10.1097/01.nrl.0000252948.82865.58
doi: 10.1097/01.nrl.0000252948.82865.58
pubmed: 17495761
Pria Anand et al (2018) Multiple sclerosis and HIV: a case of multiple sclerosis-immune reconstitution inflammatory syndrome associated with antiretroviral therapy initiation. Int J STD Aids 1–4. https://doi.org/10.1177/0956462418754972
Chalkley J et al (2014) Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man. J Neurovirol 20:640–643. https://doi.org/10.1007/s13365-014-0288-9
doi: 10.1007/s13365-014-0288-9
pubmed: 25366658
Mainardi I et al (2020) Acquisition of human immunodeficiency virus infection in a patient with multiple sclerosis: could these conditions positively influence each other’s course? J Neurovirol. https://doi.org/10.1007/s13365-020-00876-7
doi: 10.1007/s13365-020-00876-7
pubmed: 32671809
Gold J et al (2015) HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. J Neurol Neurosurg Psychiatry 86:9–12. https://doi.org/10.1136/jnnp-2014-307932
doi: 10.1136/jnnp-2014-307932
pubmed: 25091370
Marge Cartau et al (2019) Progressive multifocal leukoencephalopathy: current insights. Degener Neurol Neuromusc Dis 9:109–121. https://doi.org/10.2147/DNND.S203405
Morrow Sarah A et al (2022) Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Dis 65:103995. https://doi.org/10.1016/j.msard.2022.103995
doi: 10.1016/j.msard.2022.103995
Chandrashekar Bohra et al (2017) Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control 24(4). https://doi.org/10.1177/1073274817729901
Cieron Roe et al (2015) HIV immunodynamics and multiple sclerosis. Journal of NeuroVirology, Inc. https://doi.org/10.1007/s13365-015-0381-8
Kappos L, O’Connor PW, Polman CH (2013) Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol 260(5):1388–1395
Florio C, Maniscalco GT (2011) Improvement of visual acuity in patients with severe visual loss affected by multiple sclerosis treated with natalizumab: a case report. Neurol Sci 31(Suppl 3):325–327. https://doi.org/10.1007/s10072-010-0349-7
doi: 10.1007/s10072-010-0349-7
pubmed: 20596742
Balcer LJ, Galetta SL, Calabresi PA et al (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68(16):1299–1304. https://doi.org/10.1212/01.wnl.0000259521.14704.a8
doi: 10.1212/01.wnl.0000259521.14704.a8
pubmed: 17438220
Patel A et al (2021) Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neur 78(6):736–740. https://doi.org/10.1001/jamaneurol.2021.0627
doi: 10.1001/jamaneurol.2021.0627
Puig Casadevall M et al (2022) Progressive multifocal encephalopathy in the first patient with relapsing-remitting multiple sclerosis treated with ocrelizumab. Mult Scler J 28(Suppl.): 679–680 abstr. P780, No. 3. https://doi.org/10.1177/13524585221123687 [abstract]
Tugemann B, Berger JR (2021) Improving risk-stratification of natalizumab-associated PML. Ann Clin Transl Neurol 8(3):696–703. https://doi.org/10.1002/acn3.51130
doi: 10.1002/acn3.51130
pubmed: 33539683
pmcid: 7951098